NEFL and oculocutaneous albinism type 1: Currently, monitoring ATN pathologies in cerebrospinal fluid (CSF) (i.e., via the quantification of Aβ42 or Aβ42/Aβ40 for A, Ptau for T, and total tau (Ttau) or neurofilament light (NfL) for N) or by imaging techniques is an established way to more accurately diagnose AD and select AD patients for clinical trials [2].